JP2007500240A - Ａｂｔ−７５１による持続投与レジメン - Google Patents

Ａｂｔ−７５１による持続投与レジメン Download PDF

Info

Publication number
JP2007500240A
JP2007500240A JP2006533503A JP2006533503A JP2007500240A JP 2007500240 A JP2007500240 A JP 2007500240A JP 2006533503 A JP2006533503 A JP 2006533503A JP 2006533503 A JP2006533503 A JP 2006533503A JP 2007500240 A JP2007500240 A JP 2007500240A
Authority
JP
Japan
Prior art keywords
tubulin
subunit
therapeutically acceptable
drug
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006533503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007500240A5 (https=
Inventor
ゴードン，ギヤリー
ハージイ，アン・イー
ローゼンバーグ，ソール・エイチ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/447,588 external-priority patent/US20040242649A1/en
Priority claimed from US10/857,235 external-priority patent/US20050075395A1/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of JP2007500240A publication Critical patent/JP2007500240A/ja
Publication of JP2007500240A5 publication Critical patent/JP2007500240A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006533503A 2003-05-29 2004-06-01 Ａｂｔ−７５１による持続投与レジメン Pending JP2007500240A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/447,588 US20040242649A1 (en) 2003-05-29 2003-05-29 Extended dosing regimen
US10/842,667 US20040242650A1 (en) 2003-05-29 2004-05-10 Extended dosing regimen
US10/857,235 US20050075395A1 (en) 2003-05-28 2004-05-28 Continuous dosing regimen
PCT/US2004/016973 WO2004105794A2 (en) 2003-05-29 2004-06-01 Continuous dosing regimen with abt-751

Publications (2)

Publication Number Publication Date
JP2007500240A true JP2007500240A (ja) 2007-01-11
JP2007500240A5 JP2007500240A5 (https=) 2007-06-14

Family

ID=33494089

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006533503A Pending JP2007500240A (ja) 2003-05-29 2004-06-01 Ａｂｔ−７５１による持続投与レジメン

Country Status (6)

Country Link
US (2) US20070191437A1 (https=)
EP (1) EP1644008B1 (https=)
JP (1) JP2007500240A (https=)
CA (1) CA2526385C (https=)
MX (1) MXPA05012814A (https=)
WO (1) WO2004105794A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025147181A1 (ko) * 2024-01-05 2025-07-10 주식회사 큐피크바이오 튜불린 저해제를 포함하는 탈모 예방 또는 치료용 조성물

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117903A1 (en) * 2004-05-28 2005-12-15 Abbott Laboratories Treatment of cancer in pediatric patients
EP1836170A1 (en) * 2005-01-13 2007-09-26 Abbott Laboratories N-((2z)-2-((4-hydroxyphenyl)imino)-1,2-dihydro-3-pyridinyl)-4-methoxybenzenesulfonamide crystalline form 2
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
DK1838674T3 (da) * 2005-01-14 2011-06-14 Chemocentryx Inc Heteroarylsulfonamider og CCR2
JP5306344B2 (ja) 2007-07-12 2013-10-02 ケモセントリックス， インコーポレイテッド 炎症の治療のためのｃｃｒ２モジュレーターとしての縮合ヘテロアリールピリジルおよびフェニルベンゼンスルホンアミド
US20170293738A1 (en) * 2016-04-08 2017-10-12 International Business Machines Corporation Cognitive Adaptation of Patient Medications Based on Individual Feedback
RU2765737C2 (ru) 2016-11-23 2022-02-02 Хемоцентрикс, Инк. Способ лечения фокально-сегментарного гломерулосклероза
RU2020113612A (ru) 2017-10-11 2021-11-12 Хемоцентрикс, Инк. Лечение фокально-сегментарного гломерулосклероза антагонистами ccr2
WO2025147180A1 (ko) * 2024-01-05 2025-07-10 주식회사 큐피크바이오 튜불린 저해제를 포함하는 피부 질환 예방 또는 치료용 조성물
KR20250108066A (ko) * 2024-01-05 2025-07-15 주식회사 큐피크바이오 튜불린 저해제를 포함하는 병용요법을 이용한 피부 질환 예방 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1275922C (en) * 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
DE69129611T2 (de) * 1990-08-20 1998-12-17 Eisai Co., Ltd., Tokio/Tokyo Sulfonamid-Derivate
US6500858B2 (en) * 1994-10-28 2002-12-31 The Research Foundation Of The State University Of New York Taxoid anti-tumor agents and pharmaceutical compositions thereof
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
AUPO665397A0 (en) * 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
JP4454151B2 (ja) * 1998-06-17 2010-04-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 大環状類似体及びそれらの使用並びに調製方法
US20020128228A1 (en) * 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN5006016140, ＨＡＮＤＥ， Ｋ．， ｅｔ ａｌ．, "Ａ Ｐｈａｓｅ Ｉ ｔｒｉａｌ ｏｆ ＡＢＴ−７５１， ａ ｎｏｖｅｌ ｍｉｃｒｏｔｕｂｌｉｎ Ｉｎｈｉｂｉｔｏｒ", ＥＵＲＯＰＥＡＮ ＪＯＵＲＮＡＬ ＯＦ ＣＡＮＣＥＲ, 200211, Ｖｏｌ．３８, ｐ．Ｓ４２, GB, ＰＥＲＧＡＭＯＮ ＰＲＥＳＳ *
JPN6010029033, ＹＡＭＡＭＯＴＯ， Ｋ．， ｅｔ ａｌ．, "Ｐｈａｓｅ Ｉ ｓｔｕｄｙ ｏｆ Ｅ７０１０", Ｃａｎｃｅｒ Ｃｈｅｍｏｔｈｅｒａｐｙ ａｎｄ Ｐｈａｒｍａｃｏｌｏｇｙ, 199807, Ｖｏｌ．４２， Ｎｏ．２, ｐ．１２７−１３４ *
JPN6010029038, ＫＯＹＡＮＡＧＩ， Ｎ．， ｅｔ ａｌ．, "Ｉｎ Ｖｉｖｏ Ｔｕｍｏｒ Ｇｒｏｗｔｈ Ｉｎｈｉｂｉｔｉｏｎ Ｐｒｏｄｕｃｅｄ ｂｙ ａ Ｎｏｖｅｌ Ｓｕｌｆｏｎａｍｉｄｅ， Ｅ７０１０， ａｇａｉｎｓｔ Ｒｏｄｅｎｔ ａｎｄ Ｈｕｍａｎ Ｔｕｍ", ＣＡＮＣＥＲ ＲＥＳＥＡＲＣＨ, 19940401, Ｖｏｌ．５４， Ｎｏ．７, ｐ．１７０２−１７０６ *
JPN6010029041, ＦＵＮＡＨＡＳＨＩ， Ｙ．， ｅｔ ａｌ．, "Ｅｆｆｅｃｔ ｏｆ Ｅ７０１０ ｏｎ ｌｉｖｅｒ ｍｅｔａｓｔａｓｉｓ ａｎｄ ｌｉｆｅ ｓｐａｎ ｏｆ ｓｙｎｇｅｎｅｉｃ Ｃ５７ＢＬ／６ ｍｉｃｅ ｂｅａｒｉｎｇ ｏｒｔｈｏｔｏｐｉｃａｌｌｙ ｔ", Ｃａｎｅｒ Ｃｈｅｍｏｔｈｅｒａｐｙ ａｎｄ Ｐｈａｒｍａｃｏｌｇｙ, 200102, Ｖｏｌ．４７， Ｎｏ．２, ｐ．１７９−１８４ *
JPN6010029048, ＨＡＹＡＫＡＷＡ， Ｋ．， ｅｔ ａｌ．, "ＣＯＬＬＡＢＯＲＡＴＩＶＥ ＷＯＲＫ ＴＯ ＥＶＡＬＵＡＴＥ ＴＯＸＩＣＩＴＹ ＯＮ ＭＡＬＥ ＲＥＰＲＯＤＵＣＴＩＶＥ ＯＲＧＡＮＳ ＢＹ ＲＥＰＥＡＴＥＤ ＤＯＳＥ ＳＴＵＤＩＥＳ ＩＮ ＲＡＴＳ", Ｔｈｅ Ｊｏｕｒｎａｌ ｏｆ Ｔｏｘｉｃｏｌｏｇｉｃａｌ Ｓｃｉｅｎｃｅｓ, 2000, Ｖｏｌ．２５， Ｓｐｅｃｉａｌ Ｉｓｓｕｅ, ｐ．１７３−１７８ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025147181A1 (ko) * 2024-01-05 2025-07-10 주식회사 큐피크바이오 튜불린 저해제를 포함하는 탈모 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
WO2004105794A2 (en) 2004-12-09
EP1644008A2 (en) 2006-04-12
EP1644008B1 (en) 2011-12-21
US20070191437A1 (en) 2007-08-16
US20070197607A1 (en) 2007-08-23
WO2004105794A3 (en) 2005-02-10
MXPA05012814A (es) 2007-01-25
CA2526385C (en) 2008-07-22
CA2526385A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
EP3143995B1 (en) Rapamycin derivative for the treatment of lung cancer
RU2587013C2 (ru) Комбинированная химиотерапия
JP5911929B2 (ja) 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬
AU5092199A (en) Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
JP2007500240A (ja) Ａｂｔ−７５１による持続投与レジメン
JP2007500240A5 (https=)
WO2004081012A1 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
US11571422B2 (en) Composition including rilpivirine and method for treating tumors or cancer
TWI598095B (zh) 治療或緩解高齡或末期癌症患者用之醫藥組合物
JP2010106019A (ja) リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤
US20050075395A1 (en) Continuous dosing regimen
US20050267166A1 (en) Continuous dosing regimen
HK1093423A1 (en) Continuous dosing regimen with abt-751
HK1093423B (en) Continuous dosing regimen with abt-751
JP7450037B2 (ja) 脳転移を有する末期非小細胞肺がん患者を治療するための組み合わせ医薬品
HK1169603B (en) Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers
HK1232469B (en) Rapamycin derivative for the treatment of lung cancer
HK1116064B (en) Antitumor agent
HK1197723B (en) Treatment of solid brain tumours with a rapamycin derivative
HK1116064A1 (en) Antitumor agent
HK1146245B (en) Treatment of solid kidney tumours with a rapamycin derivative

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20070417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100601

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101026